Cross-sectoral Coordination Meeting related to Shipment of Materials

IASMED attended a discussion session held by BB Binomika on 30 April. The key topic of this discussion is about the policy, regulation, and procedures relating to clinical trials, Material Transfer Agreement (MTA), Special Access Scheme (SAS), and Import-Export process of clinical trial materials. It was a rich discussion with important industry players who openly shared insights about the current operational hurdles as well as success stories.

IASMED is really excited and grateful to be in this era of breakthrough. Some recent improvements related to MTA has catalyzed processes of many ongoing studies. Reportedly, during the past 1 year only, 44 new MTAs have been approved, consisting of MTA for both clinical trials and non-clinical trials. Despite the numbers already worth of applauses, forum discussion like this is a proof that BB Binomika doesn’t want to stop there. They aim for continuous improvements and operational excellence, which give us a peace of mind that our ecosystem is truly on the right track. Thank you, BB Binomika, and let’s keep moving forward!